Intellia Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Okay. Great. My name is Gena Wang. I'm speaking of biotech analyst at the Barclays. Thank you for coming to our first in-person Global Healthcare Conference post pandemic. It is really nice to see everyone in person. I wanted to thank everyone, investors, companies, especially (inaudible) team who made this event possible.
With that, it's my great pleasure to introduce our next presenting company, Intellia. With us today, we have John Leonard, President and Chief Executive Officer.
John, do you want to give a very brief introduction before we dive into the questions?
Sure. Sure. Thank you. I can -- real quickly I can kind of lay out what Intellia is. We call ourselves a full spectrum (inaudible) company, which means we have really 3 legs to the stool, a very, very active in vivo effort where we emphasize systemically administered CRISPR/Cas9. I'm sure we'll be talking about that.
We also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |